Centessa Pharmaceuticals plc (NASDAQ:CNTA) Receives $25.17 Average Price Target from Brokerages

Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) have received an average rating of “Buy” from the six analysts that are covering the stock, Marketbeat Ratings reports. Six investment analysts have rated the stock with a buy rating. The average 1 year target price among brokerages that have covered the stock in the last year is $25.17.

A number of brokerages recently commented on CNTA. Jefferies Financial Group raised their price target on Centessa Pharmaceuticals from $13.00 to $19.00 and gave the stock a “buy” rating in a research note on Wednesday, September 11th. Guggenheim raised their target price on shares of Centessa Pharmaceuticals from $20.00 to $24.00 and gave the stock a “buy” rating in a research report on Wednesday, September 11th. B. Riley began coverage on shares of Centessa Pharmaceuticals in a research report on Thursday, September 19th. They set a “buy” rating and a $33.00 price target on the stock. BMO Capital Markets raised their price objective on shares of Centessa Pharmaceuticals from $20.00 to $35.00 and gave the stock an “outperform” rating in a report on Monday, September 16th. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $14.00 price objective on shares of Centessa Pharmaceuticals in a research report on Wednesday, August 14th.

Insider Activity at Centessa Pharmaceuticals

In other Centessa Pharmaceuticals news, CEO Saurabh Saha sold 4,169 shares of the company’s stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $12.32, for a total value of $51,362.08. Following the sale, the chief executive officer now owns 827,755 shares in the company, valued at approximately $10,197,941.60. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, CEO Saurabh Saha sold 4,169 shares of the company’s stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $12.32, for a total value of $51,362.08. Following the transaction, the chief executive officer now owns 827,755 shares in the company, valued at $10,197,941.60. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Gregory M. Weinhoff sold 16,619 shares of the firm’s stock in a transaction dated Wednesday, September 25th. The shares were sold at an average price of $15.69, for a total transaction of $260,752.11. Following the sale, the insider now owns 206,750 shares of the company’s stock, valued at approximately $3,243,907.50. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 288,492 shares of company stock valued at $4,641,902 in the last three months. Company insiders own 11.59% of the company’s stock.

Hedge Funds Weigh In On Centessa Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the company. Quarry LP purchased a new stake in Centessa Pharmaceuticals during the 4th quarter valued at $48,000. China Universal Asset Management Co. Ltd. increased its holdings in Centessa Pharmaceuticals by 69.2% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 10,817 shares of the company’s stock worth $122,000 after buying an additional 4,423 shares in the last quarter. Acadian Asset Management LLC purchased a new position in Centessa Pharmaceuticals in the 1st quarter worth about $330,000. Platinum Investment Management Ltd. lifted its stake in Centessa Pharmaceuticals by 27.3% during the 1st quarter. Platinum Investment Management Ltd. now owns 485,174 shares of the company’s stock valued at $5,482,000 after acquiring an additional 104,091 shares during the period. Finally, EntryPoint Capital LLC purchased a new stake in shares of Centessa Pharmaceuticals during the 1st quarter valued at about $109,000. 82.01% of the stock is currently owned by hedge funds and other institutional investors.

Centessa Pharmaceuticals Stock Performance

Shares of NASDAQ:CNTA opened at $16.29 on Monday. The company has a current ratio of 13.29, a quick ratio of 13.29 and a debt-to-equity ratio of 0.27. The company has a 50-day moving average price of $14.50 and a 200-day moving average price of $11.28. The company has a market cap of $1.64 billion, a price-to-earnings ratio of -11.47 and a beta of 1.46. Centessa Pharmaceuticals has a 12 month low of $5.58 and a 12 month high of $17.59.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.02). As a group, equities analysts anticipate that Centessa Pharmaceuticals will post -1.68 EPS for the current year.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.